Brokers Offer Predictions for EW Q1 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Edwards Lifesciences in a research note issued to investors on Wednesday, February 12th. William Blair analyst M. Andrew forecasts that the medical research company will earn $0.65 per share for the quarter. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.56 per share. William Blair also issued estimates for Edwards Lifesciences’ Q2 2026 earnings at $0.68 EPS, Q3 2026 earnings at $0.67 EPS and Q4 2026 earnings at $0.72 EPS.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%.

Several other research firms also recently issued reports on EW. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday. Robert W. Baird dropped their target price on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. Finally, Barclays raised their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Stock Performance

NYSE EW opened at $76.23 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a market capitalization of $44.96 billion, a PE ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10. The company has a fifty day moving average of $72.67 and a two-hundred day moving average of $69.50.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors have recently modified their holdings of the stock. Harbor Capital Advisors Inc. grew its position in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company’s stock worth $824,000 after purchasing an additional 273 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Edwards Lifesciences by 34.6% during the fourth quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after buying an additional 1,043,484 shares in the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST boosted its holdings in Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company’s stock worth $355,344,000 after buying an additional 300,000 shares in the last quarter. Sivik Global Healthcare LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $3,702,000. Finally, Avanza Fonder AB bought a new stake in Edwards Lifesciences during the fourth quarter worth approximately $4,845,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 26,489 shares of company stock valued at $2,002,829. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.